<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975971</url>
  </required_header>
  <id_info>
    <org_study_id>AVC-004</org_study_id>
    <nct_id>NCT04975971</nct_id>
  </id_info>
  <brief_title>A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery</brief_title>
  <official_title>A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicole Fram M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Vision Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received&#xD;
      DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal&#xD;
      transplant or Cataract surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received&#xD;
      DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert, placed within the lower or upper eye&#xD;
      lid canaliculus in conjunction with topical steroid Prior to or Following Corneal transplant&#xD;
      or Cataract surgery&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Actual">May 19, 2021</completion_date>
  <primary_completion_date type="Actual">May 19, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in pain score</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>As measured with the visual analog scale (VAS); between 0 and 100; 0 meaning no pain and 100 meaning worse pain possible</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in inflammation (Cell and Flare) scores</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>As measured by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of pain</measure>
    <time_frame>Assessed for 1 months after drug insertion</time_frame>
    <description>Resolution of pain as assessed by aquestionnaire in post-op visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of anterior chamber inflammation</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>Resolution of anterior chamber inflammation as measured by SUN grading at the slitlamp in post-op visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of eyes requiring additional post-operative therapy</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>Proportion of eyes requiring additional post-operative therapy for pain and inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient call-backs regarding post-operative pain</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>Number of patient call-backs regarding post-operative pain and medication management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pharmacy call-backs regarding post-operative medication</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>Number of pharmacy call-backs regarding post-operative medication management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>Incidence and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in IOP</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>Mean change in IOP over post-op visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BCVA</measure>
    <time_frame>Assessed for 3 months after drug insertion</time_frame>
    <description>Change in BCVA over post op visits</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Anterior Chamber Inflammation</condition>
  <condition>Ocular Pain</condition>
  <condition>Corneal Edema</condition>
  <condition>Corneal Defect</condition>
  <condition>Penetrating KeratoPlasty</condition>
  <condition>Nuclear Cataract</condition>
  <condition>Cortical Cataract</condition>
  <condition>Cataract Senile</condition>
  <arm_group>
    <arm_group_label>Dextenza recepient</arm_group_label>
    <description>A Retrospective Review DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal Transplant or Cataract Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Ophthalmic Insert</intervention_name>
    <description>DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.</description>
    <arm_group_label>Dextenza recepient</arm_group_label>
    <other_name>Dexamethasone 0.4mg</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will evaluate n=25 (25 eyes) who underwent corneal transplant or cataract surgery&#xD;
        and received DEXTENZA insertion prior to or following surgery as documented in E.H.R&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Patients who received DEXTENZA insertion perioperatively.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who did not receive DEXTENZA insertion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole R Fram, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Vision Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Vision Care</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dextenza.com/wp-content/uploads/2019/06/NDA-208742-S001-Dextenza-labeling-19Jun19.pdf</url>
    <description>Dextenza (dexamethasone insert) Prescribing Information, Ocular Therapeutix,Inc.2019</description>
  </link>
  <link>
    <url>http://doi.org/10.17925/EOR.2012.06.02.98</url>
    <description>Treatment of Post-operative Inflammation following Cataract Surgery - A Review Published Online: May 3rd 2012 European Ophthalmic Review, 2012;6(2):98-103 DOI: http://doi.org/10.17925/EOR.2012.06.02.98</description>
  </link>
  <link>
    <url>http://doi.org/10.1111/aos.13055</url>
    <description>Recovery after cataract surgery</description>
  </link>
  <link>
    <url>http://doi.org/10.4172/2155-9570.1000572</url>
    <description>Efficacy and Safety of Sustained Release Dexamethasone for theTreatment of Ocular Pain and Inflammation after Cataract Surger</description>
  </link>
  <results_reference>
    <citation>Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24. Erratum in: J Cataract Refract Surg. 2019 Jun;45(6):895.</citation>
    <PMID>30367938</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Advanced Vision Care</investigator_affiliation>
    <investigator_full_name>Nicole Fram M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Corneal Edema</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

